Market Overview - The three major stock indices experienced a rally, with the ChiNext Index rising over 1% at one point. The Shanghai Composite Index closed up 0.38% at 3380.48 points, the Shenzhen Component Index rose 0.77% to 10249.17 points, and the ChiNext Index increased by 0.77% to 2048.46 points. The Northbound 50 Index saw a gain of 1.22%. The total trading volume in the Shanghai and Shenzhen markets reached 1211.4 billion yuan, an increase of 92.3 billion yuan from the previous day [1]. Wind Power Industry - The wind turbine sector is expected to see a fundamental turning point, with major domestic wind turbine manufacturers reporting a year-on-year increase of over 40% in orders by the end of 2024. The first quarter of 2025 is anticipated to be strong for wind turbine shipments, leading to potential over-expectation growth in industry installations and revenues. The profitability of leading wind turbine manufacturers is expected to stabilize and recover by the second half of 2024, with a projected gross margin recovery of over 6.5 percentage points in the next two years [2]. Pharmaceutical Industry - On May 20, 2023, 3SBio announced a partnership with Pfizer, granting exclusive global rights (excluding mainland China) for the development, production, and commercialization of the PD-1/VEGF bispecific antibody SSGJ-707. 3SBio retains rights for SSGJ-707 in mainland China and will grant Pfizer an option for commercialization in that region based on agreed financial terms [3]. - The domestic innovative drug market is expected to benefit from policy and industry trends, with valuations set for recovery. The market size for innovative drugs in China is projected to grow from $132.5 billion in 2019 to $159.2 billion in 2024, maintaining a global market share of around 15%. In the first quarter of 2025, there were 41 license-out transactions totaling $36.9 billion, setting a new historical high for the same period [4]. Alcohol Industry - Recent revisions to the "Regulations on Strict Economy and Opposition to Waste by Party and Government Agencies" are expected to have a limited impact on the liquor industry. Leading liquor companies are enhancing shareholder returns through increased dividends, buybacks, and shareholdings. The outlook for the consumption stimulus policies and macroeconomic recovery supports continued investment in leading liquor brands [5].

Industry Insights - The Chinese government aims to establish a globally leading IPv6 technology, industry, infrastructure, application, and security system by the end of 2025, with active IPv6 users reaching 850 million and IoT IPv6 connections hitting 1.1 billion [1] - The 2024 Global IPv6 Support Rate White Paper indicates that the global IPv6 deployment rate will reach 39.4% in 2024, with significant growth in Asia and the Americas, where deployment rates are expected to exceed 45% [1] Application Scenarios - In the smart manufacturing sector, IPv6 enables the allocation of unique IP addresses to every camera in a facility, facilitating the high-speed aggregation and retrieval of vast amounts of ultra-high-definition video, thus enhancing industrial digitalization and intelligence [2] - In the smart healthcare field, IPv6 supports the online allocation of IP addresses for numerous medical devices, promoting the advancement of telemedicine and allowing doctors to control medical equipment more precisely [2] - In the smart city domain, IPv6 serves as the foundational technology for the new generation of e-government networks, driving the transformation and upgrading of government platforms [2] Company Involvement - Wangsu Technology has been actively supporting the national IPv6 initiative since 2013, indicating its commitment to the advancement of IPv6 deployment [3] - Advanced Data Technology offers specialized technical solutions, including SDN intelligent networks, IPv6 upgrades, and data center migration projects, showcasing its involvement in the IPv6 transition [4]